Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julius J Deren

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Digestive Diseases and Sciences|June 7, 2007
Bowman-Birk inhibitor concentrate: a novel therapeutic agent for patients with active ulcerative colitisGary R Lichtenstein, Julius J Deren, Seymour Katz, et al.
The American Journal of Gastroenterology|October 19, 2002
Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitisChinyu Su, Bruce A Salzberg, James D Lewis, et al.
Gastroenterology|March 8, 2008
Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trialJames D Lewis, Gary R Lichtenstein, Julius J Deren, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Digestive Diseases and Sciences|June 7, 2007
Bowman-Birk inhibitor concentrate: a novel therapeutic agent for patients with active ulcerative colitisGary R Lichtenstein, Julius J Deren, Seymour Katz, et al.
The American Journal of Gastroenterology|October 19, 2002
Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitisChinyu Su, Bruce A Salzberg, James D Lewis, et al.
Gastroenterology|March 8, 2008
Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trialJames D Lewis, Gary R Lichtenstein, Julius J Deren, et al.
Pageof 1